Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID KAVTARADZE

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1376516484
CMS profile
16477
Location
CORDELE, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,422.97

84 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,422.97 84

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID KAVTARADZE

NPI 1376516484 · CMS profile ID 16477

Allopathic & Osteopathic Physicians / Internal Medicine

CORDELE, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1376516484?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID KAVTARADZE, NPI 1376516484, CMS profile ID 16477. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1376516484?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). DAVID KAVTARADZE, NPI 1376516484, CMS profile ID 16477. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1376516484?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
DAVID KAVTARADZE, NPI 1376516484, CMS profile ID 16477, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1376516484?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

84 matching records · $1,422.97 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 84 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–84 of 84.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $22.5905/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097241790 CMS
GlaxoSmithKline, LLC. $24.0005/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116635872 CMS
GlaxoSmithKline, LLC. $4.5305/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116243568 CMS
Merck Sharp & Dohme LLC $17.3005/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141924972 CMS
ABBVIE INC. $14.9805/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104043470 CMS
Phathom Pharmaceuticals, Inc. $19.4604/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151080292 CMS
AstraZeneca Pharmaceuticals LP $17.8004/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105446389 CMS
GlaxoSmithKline, LLC. $8.3604/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116078670 CMS
Merck Sharp & Dohme LLC $18.7904/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141658726 CMS
GlaxoSmithKline, LLC. $23.4804/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115816260 CMS
AstraZeneca Pharmaceuticals LP $18.0603/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104360421 CMS
Lilly USA, LLC $17.8303/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136149975 CMS
Bayer Healthcare Pharmaceuticals Inc. $16.0403/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086261194 CMS
AstraZeneca Pharmaceuticals LP $15.0203/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105818207 CMS
Merck Sharp & Dohme LLC $17.6703/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141855994 CMS
Lilly USA, LLC $15.8503/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136127265 CMS
AstraZeneca Pharmaceuticals LP $14.8503/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104213781 CMS
Lundbeck LLC $18.2003/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145932131 CMS
Novo Nordisk Inc $9.1602/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097590390 CMS
AstraZeneca Pharmaceuticals LP $18.4402/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104403865 CMS
Merck Sharp & Dohme LLC $16.4802/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141658728 CMS
GlaxoSmithKline, LLC. $22.0202/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116732746 CMS
AstraZeneca Pharmaceuticals LP $14.8502/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105505470 CMS
Lilly USA, LLC $16.7001/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136124585 CMS
PFIZER INC. $17.8201/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131168305 CMS
PFIZER INC. $25.9901/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130994046 CMS
GlaxoSmithKline, LLC. $9.1901/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116302605 CMS
Bayer Healthcare Pharmaceuticals Inc. $15.5501/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086220405 CMS
SHIELD THERAPEUTICS INC $16.5301/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150116867 CMS
Otsuka America Pharmaceutical, Inc. $16.1301/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118919614 CMS
Lilly USA, LLC $15.6501/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136124587 CMS
AstraZeneca Pharmaceuticals LP $16.8101/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104286366 CMS
AstraZeneca Pharmaceuticals LP $30.5901/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104499536 CMS
Novo Nordisk Inc $22.6801/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096683552 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $9,220.05 132
PY2020 $1,637.82 108
PY2021 $1,816.25 112
PY2022 $1,768.84 101
PY2023 $1,826.02 104
PY2024 $1,422.97 84
PY2025 $854.29 47

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $962,437.83 62
PY2024 Principal investigator $1,099,753.19 58
PY2023 Principal investigator $308,076.38 34
PY2022 Principal investigator $73,347.78 26

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

62 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $17,708.00 12/22/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121844
Principal investigator 1 SANOFI US SERVICES INC. $87,809.00 12/17/2025 Non-covered Recipient Entity
National Clinical Trials Inc
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226101003
Principal investigator 1 CSL Behring $6,337.00 12/15/2025 Non-covered Recipient Entity
National Clinical Trials
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252670098
Principal investigator 1 AstraZeneca Pharmaceuticals LP $16,350.00 12/10/2025 Non-covered Recipient Entity
MD TRIALS LLC
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure No dispute reported 06/30/2026 1185544423
Principal investigator 1 SANOFI US SERVICES INC. $33,154.00 12/10/2025 Non-covered Recipient Entity
National Clinical Trials Inc
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype No dispute reported 06/30/2026 1226100997
Principal investigator 1 SANOFI US SERVICES INC. $4,300.00 12/08/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226121828
Principal investigator 1 SANOFI US SERVICES INC. $18,596.00 12/08/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121831
Principal investigator 1 SANOFI US SERVICES INC. $16,500.00 12/08/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121835
Principal investigator 1 SANOFI US SERVICES INC. $8,716.00 11/24/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121825
Principal investigator 1 GlaxoSmithKline, LLC. $4,000.00 11/21/2025 Non-covered Recipient Entity
CONDUCT CLINICAL TRIALS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192111002
Principal investigator 1 SANOFI US SERVICES INC. $34,549.00 10/30/2025 Non-covered Recipient Entity
National Clinical Trials Inc
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226100985
Principal investigator 1 GlaxoSmithKline, LLC. $2,125.00 10/15/2025 Non-covered Recipient Entity
CONDUCT CLINICAL TRIALS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192110990
Principal investigator 1 GlaxoSmithKline, LLC. $13,150.00 10/15/2025 Non-covered Recipient Entity
CONDUCT CLINICAL TRIALS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192110997
Principal investigator 1 SANOFI US SERVICES INC. $17,595.00 10/03/2025 Non-covered Recipient Entity
National Clinical Trials Inc
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226100959
Principal investigator 1 SANOFI US SERVICES INC. $600.00 09/29/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121752
Principal investigator 1 SANOFI US SERVICES INC. $200.00 09/26/2025 Non-covered Recipient Entity
National Clinical Trials Inc
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226100953
Principal investigator 1 SANOFI US SERVICES INC. $1,594.00 09/22/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121747
Principal investigator 1 SANOFI US SERVICES INC. $15,750.00 09/12/2025 Non-covered Recipient Entity
National Clinical Trials Inc
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype No dispute reported 06/30/2026 1226100924
Principal investigator 1 CSL Behring $7,827.00 09/11/2025 Non-covered Recipient Entity
National Clinical Trials
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252670094
Principal investigator 1 SANOFI US SERVICES INC. $7,736.00 08/28/2025 Non-covered Recipient Entity
National Clinical Trials Inc
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226100888
Principal investigator 1 SANOFI US SERVICES INC. $100.00 08/28/2025 Non-covered Recipient Entity
National Clinical Trials Inc
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226100892
Principal investigator 1 SANOFI US SERVICES INC. $5,300.00 08/28/2025 Non-covered Recipient Entity
National Clinical Trials Inc
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226100931
Principal investigator 1 SANOFI US SERVICES INC. $21,200.00 08/28/2025 Non-covered Recipient Entity
National Clinical Trials Inc
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226100939
Principal investigator 1 SANOFI US SERVICES INC. $63,410.00 08/18/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121734
Principal investigator 1 SANOFI US SERVICES INC. $13,967.00 08/08/2025 Non-covered Recipient Entity
National Clinical Trials Inc
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226100851
Principal investigator 1 SANOFI US SERVICES INC. $50.00 08/08/2025 Non-covered Recipient Entity
National Clinical Trials Inc
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226100858
Principal investigator 1 AstraZeneca Pharmaceuticals LP $18,850.00 08/07/2025 Non-covered Recipient Entity
MD TRIALS LLC
Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185544421
Principal investigator 1 SANOFI US SERVICES INC. $39,600.00 07/21/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121701
Principal investigator 1 SANOFI US SERVICES INC. $215.36 07/14/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226121698
Principal investigator 1 SANOFI US SERVICES INC. $200.00 07/14/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121726
Principal investigator 1 SANOFI US SERVICES INC. $8,537.00 07/11/2025 Non-covered Recipient Entity
National Clinical Trials Inc
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226100835
Principal investigator 1 SANOFI US SERVICES INC. $24,336.00 06/23/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121713
Principal investigator 1 SANOFI US SERVICES INC. $36,201.00 05/27/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121678
Principal investigator 1 SANOFI US SERVICES INC. $13,534.00 05/05/2025 Non-covered Recipient Entity
National Clinical Trials Inc
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226100780
Principal investigator 1 SANOFI US SERVICES INC. $10,447.62 05/05/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226121654
Principal investigator 1 SANOFI US SERVICES INC. $110,376.00 04/28/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121658
Principal investigator 1 SANOFI US SERVICES INC. $2,475.00 04/14/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121663
Principal investigator 1 SANOFI US SERVICES INC. $107.68 04/14/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226121666
Principal investigator 1 SANOFI US SERVICES INC. $100.00 04/14/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121671
Principal investigator 1 SANOFI US SERVICES INC. $197.00 04/07/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121613
Principal investigator 1 SANOFI US SERVICES INC. $22,690.47 04/07/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226121634
Principal investigator 1 SANOFI US SERVICES INC. $1,800.00 04/02/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121618
Principal investigator 1 SANOFI US SERVICES INC. $91.53 04/02/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226121621
Principal investigator 1 SANOFI US SERVICES INC. $91.53 04/02/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121626
Principal investigator 1 SANOFI US SERVICES INC. $500.00 04/02/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121629
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 04/02/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1226121632
Principal investigator 1 SANOFI US SERVICES INC. $56,819.00 03/24/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121575
Principal investigator 1 SANOFI US SERVICES INC. $395.54 03/24/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121602
Principal investigator 1 SANOFI US SERVICES INC. $550.00 03/17/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226121546
Principal investigator 1 SANOFI US SERVICES INC. $30,957.74 03/17/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226121550
Principal investigator 1 SANOFI US SERVICES INC. $1,375.00 03/10/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121541
Principal investigator 1 SANOFI US SERVICES INC. $625.00 03/10/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121566
Principal investigator 1 SANOFI US SERVICES INC. $1,300.00 02/24/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226121561
Principal investigator 1 SANOFI US SERVICES INC. $347.50 02/24/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226121569
Principal investigator 1 SANOFI US SERVICES INC. $387.52 02/18/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226121516
Principal investigator 1 SANOFI US SERVICES INC. $51,374.80 02/18/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226121520
Principal investigator 1 SANOFI US SERVICES INC. $1,300.00 02/18/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226121523
Principal investigator 1 SANOFI US SERVICES INC. $98.50 02/18/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226121527
Principal investigator 1 SANOFI US SERVICES INC. $17,776.00 02/18/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121530
Principal investigator 1 SANOFI US SERVICES INC. $34,211.78 02/18/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226121554
Principal investigator 1 SANOFI US SERVICES INC. $34,351.26 02/18/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226121590
Principal investigator 1 SANOFI US SERVICES INC. $20,595.00 02/18/2025 Non-covered Recipient Entity
Md Trials Llc Conduct Clinical Trials
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121598